Comparison of the effects of firocoxib, carprofen and vedaprofen in a sodium urate crystal induced synovitis model of arthritis in dogs

Research in Veterinary Science

Volumn 84, Issue 1, 2008, Pages 74-79

  Hazewinkel, Herman A W ^a   van den Brom, Walter E ^a   Theyse, Lars F H ^a   Pollmeier, Matthias ^b   Hanson, Peter D ^b  

^a UTRECHT UNIVERSITY   (Netherlands)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Canine; Cyclooxigenase inhibitor; Inflammation; Pain; Synovitis model of arthritis

Indexed keywords

CARPROFEN; CYCLOOXYGENASE 2 INHIBITOR; FIROCOXIB; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PREVICOX; QUADRISOL; UNCLASSIFIED DRUG; URATE; VEDAPROFEN;

ANIMAL EXPERIMENT; ANIMAL LAMENESS; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOG; DRUG EFFICACY; FEMALE; GOUT; GROUND REACTION FORCE; MALE; NONHUMAN; SCORING SYSTEM; SINGLE DRUG DOSE; SYNOVITIS; WEIGHT BEARING;

4-BUTYROLACTONE; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS; CARBAZOLES; CROSS-OVER STUDIES; DOG DISEASES; DOGS; FEMALE; LAMENESS, ANIMAL; MALE; NAPHTHALENES; PROPIONIC ACIDS; SULFONES; SYNOVITIS; TIME FACTORS; URIC ACID;

CANIS FAMILIARIS;

EID: 36049012436     PISSN: 00345288     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rvsc.2007.02.005     Document Type: Article

References (38)

1. Bockstahler, B.A., Skalicky, M., Peham, C., Müller, M., Lorinson, D., 2005. Reliability of ground reaction forces measured on a treadmill system in healthy dogs. Vet. J. [Epub ahead of print].
2. Bombardier C., Laine L., Reicin A., Shapiro D., Burgos-Vargas R., Davis B., Day R., Ferraz M.B., Hawkey C.J., Hochberg M.C., Kvien T.K., and Schnitzer T.J. VIGOR study group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N. Engl. J. Med. 343 21 (2000) 1520-1528
3. Botrel M.A., Haak T., Legrand C., Concordet D., Chevalier R., and Toutain P.L. Quantitative evaluation of an experimental inflammation induced with Freund's complete adjuvant in dogs. J. Pharmacol. Toxicol. Methods 32 2 (1994) 63-71
4. Budsberg S.C., Johnston S.A., Schwarz P.D., Decamp C.E., and Claxton R. Efficacy of etodolac for the treatment of osteoarthritis of the hip joints in dogs. J. Am. Vet. Med. Assoc. 214 2 (1999) 206-210
5. Cross A.R., Budsberg S.C., and Keefe T.J. Kinetic gait analysis assessment of meloxicam efficacy in a sodium urate-induced synovitis model in dogs. Am. J. Vet. Res. 58 6 (1997) 626-631
6. Fitzgerald G.A. Coxibs and cardiovascular disease. N. Engl. J. Med. 351 17 (2004) 1709-1711
7. Fox S.M., and Johnston S.A. Use of carprofen for the treatment of pain and inflammation in dogs. J. Am. Vet. Med. Assoc. 210 10 (1997) 1493-1498
8. Haak T., Delverdier M., Amardeilh M.F., Oswald I.P., and Toutain P.L. Pathologic study of an experimental canine arthritis induced with complete Freund's adjuvant. Clin. Exp. Rheumatol. 14 6 (1996) 633-641
9. Hanson P.D., Brooks K.C., Case J., Conzemius M., Gordon W., Schuessler J., Shelley B., Sifferman R., Drag M., Alva R., Bell L., Romano D., and Fleischman C. Efficacy and safety of firocoxib in the management of canine osteoarthritis under field conditions. Vet. Therap. 7 2 (2006) 127-140
10. Hawkey C., Laine L., Simon T., Beaulieu A., Maldonado-Cocco J., Acevedo E., Shahane A., Quan H., Bolognese J., and Mortensen E. Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. The rofecoxib osteoarthritis endoscopy multinational study group. Arthritis Rheum. 43 2 (2000) 370-377
11. Hazewinkel, H.A.W., Van den Brom, W.E., Theyse, L.F.H., Maarschalkerweerd, R.J., 1996. Force plate analysis of locomotion in dogs. In: Proceedings of Fifth Annual Scientific Meeting, European College of Veterinary Surgeons, Utrecht, The Netherlands, 28-30 June 1996: 129-130.
12. Hazewinkel H.A.W., Van den Brom W.E., Theyse L.F.H., Pollmeier M., and Hanson P.D. Reduced dosage of ketoprofen for the short-term and long-term treatment of joint pain in dogs. Vet. Rec. 152 1 (2003) 11-14
13. Jenkins W.L. Pharmocological aspects of analgesic drugs in animals: an overview. J. Am. Vet. Med. Assoc. 191 10 (1987) 1231-1240
14. Klee S., and Ungemach F.R. Pharmakotherapie degenerativer Gelenkerkrankungen beim Hund. Tierärztliche Praxis 26 (1998) 1-6
15. Kore A.M. Toxicology of nonsteroidal anti-inflammatory drugs. Vet. Clin. North. Am. Small Anim. Pract. 20 2 (1990) 419-430
16. Lanza F.L., Rack M.F., Simon T.J., Quan H., Bolognese J.A., Hoover M.E., Wilson F.R., and Harper S.E. Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen. Aliment. Pharmacol. Ther. 13 6 (1999) 761-767
17. Lipscomb V.J., Aliabadi F.S., Lees P., Pead M.J., and Muir P. Clinical efficacy and pharmacokinetics of carprofen in the treatment of dogs with osteoarthritis. Vet. Rec. 150 22 (2002) 684-689
18. McCann M.E., Andersen D.R., Rickes E.L., Brideau C., Black W.C., Zhang D.H., and Hickey G.J. In vitro activity and in vivo efficacy of a novel cox-2 inhibitor in dogs and cats (abstract). J. Vet. In. Med. 16 (2002) 356
19. McCann M.E., Andersen D.R., Zhang D.H., Brideau C., Black W.C., Hanson P.D., and Hickey G.J. In vitro effects and in vivo efficacy of a novel cyclooxygenase-2 inhibitor in dogs with experimentally induced synovitis. Am. J. Vet. Res. 65 4 (2004) 503-512
20. McCarty D.J., Phelps P., and Pyenson J. Crystal-induced inflammation in canine joints. I. An experimental model with quantification of the host response. J. Exp. Med. 124 1 (1966) 99-114
21. Millis D.L., Weigel J.P., Moyers T., and Buonomo F.C. Effect of deracoxib, a new cox-2 inhibitor, on the prevention of lameness induced by chemical synovitis in dogs. Vet. Ther. 3 4 (2002) 453-464
22. Mitchell J.A., Larkin S., and Williams T.J. Cyclooxigenase-2: regulation and relevance in inflammation. Biochem. Pharmacol. 50 10 (1995) 1535-1542
23. Phelps P., Prockop D.J., and McCarty D.J. Crystal induced inflammation in canine joints. III. Evidence against bradykinin as a mediator of inflammation. J. Lab. Clin. Med. 68 3 (1966) 433-444
24. Pollmeier M., Toulemonde C., Fleishman C., and Hanson P.D. Clinical evaluation of firocoxib and carprofen for the treatment of dogs with osteoarthritis. Vet. Rec. 159 17 (2006) 547-551
25. Pond M.J., and Nuki G. Experimentally-induced osteoarthritis in the dog. Ann. Rheum. Dis. 32 4 (1973) 387-388
26. Rubin S.I. Nonsteroidal antiinflammatory drugs; prostaglandins, and the kidney. J. Am. Vet. Med. Assoc. 188 (1986) 1065-1068
27. Rumph P.F., Kincaid S.A., Baird D.K., Kammermann J.R., Visco D.M., and Goetze L.F. Vertical ground force distribution during experimentally induced acute synovitis in dogs. Am. J. Vet. Res. 54 3 (1993) 365-369
28. Rumph P.F., Kincaid S.A., Visco D.M., Baird D.K., Kammermann J.R., and West M.S. Redistribution of vertical ground force in dogs with experimentally induced chronic hindlimb lameness. Vet. Surg. 24 5 (1995) 384-389
29. Schumacher H.R., Phelps P., and Agudelo C.A. Urate crystal induced inflammation in dog joints: sequence of synovial changes. J. Rheumatol. 1 1 (1974) 102-113
30. Seibert K., and Masferrer J.L. Role of inducible cyclooxigenase (cox-2) in inflammation. Receptor 4 (1994) 17-23
31. Seibert K., Zhang Y., Leahy K., Hauser S., Masferrer J.L., Perkins W., Lee L., and Isakson P. Pharmacological and biochemical demonstration of the role of cyclooxigenase 2 in inflammation and pain. Proc. National Aca. Sci. 91 25 (1994) 12013-12017
32. Theijse L.F.H., Hazewinkel H.A.W., and Van den Brom W.E. Force plate analyses before and after surgical treatment of unilateral fragmented coronoid process. Vet. Comp. Orthop. Traumatol. 13 (2000) 135-140
33. Toutain P.L., Cester C.C., Haak T., and Laroute V.J. A pharmacokinetic/pharmacodynamic approach vs. a dose titration for the determination of a dosage regimen: the case of nimesulide, a COX-2 selective nonsteroidal anti-inflammatory drug in the dog. J. Vet. Pharmacol. Ther. 24 1 (2001) 43-55
34. Vane, J.R., Botting, R.M., 1996. The history of anti-inflammatory drugs and their mechanism of action. In: Bazan, N.G., Botting, J., Vane, J.R. (Eds.), Proceedings of the New Targets in Inflammation. Inhibitors of Cox-2 or Adhesion Molecules. 15-16 April 1996, NO, USA, 1-12.
35. Vasseur B.P., Johnson A.L., Budsberg S.C., Lincoln J.D., Toombs J.P., Whitehair J.G., and Lentz E.L. Randomized, controlled trial of the efficacy of carprofen, a nonsteroidal anti-inflammatory drug, in the treatment of osteoarthritis in dogs. J. Am. Vet. Med. Assoc. 206 6 (1995) 807-811
36. Wallace M.S., Zawie D.A., and Garvey M.S. Gastric ulceration in the dog secondary to the use of nonsteroidal antiinflammatory drugs. J. Am. Anim. Hosp. Assoc. 26 (1990) 467-472
37. Watson D.J., Harper S.E., Zhao P.L., Quan H., Bolognese J.A., and Simon T.J. Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis. Arch. Intern. Med. 160 (2000) 2998-3003
38. Wiseman M.L., Nolan A.M., Reid J., and Scott E.M. Preliminary study on owner-reported behaviour changes associated with chronic pain in dogs. Vet. Rec. 149 14 (2001) 423-424